Articles & Publications , Modified Release

Scientific Paper_ Development of a Prototype, Once-Daily, Modified Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772

1 February 2021
  • Home
  • Resources
  • Scientific Paper_ Development of a Prototype, Once-Daily, Modified Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772
Overview

ABSTRACT
Purpose GSK2982772 is a selective inhibitor of receptor interacting protein kinase-1, with a 2–3 h half-life. This study evaluated if a once-daily modified-release formulation of GSK2982772 could be developed with no significant food effect.

Download
Date
1 February 2021
Ask The Experts

Solubility enhancement questions? Get answers from our team.

Have a question about your poorly soluble molecule? Ask a member of our team about our capabilities for drug product formulation, clinical or commercial manufacturing to keep your drug program on-track.

Get In Touch
Dr. Andrew Lewis

Chief Scientific Officer

Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...

About Andrew
Dr. Asma Patel

VP, Global Commercial and Scientific Consulting - Drug Product

Dr. Asma Patel is responsible for providing scientific and technical support to Quotient Sciences' business development group and ...

About Asma
Robert Cornog

Senior Director, Product Development

Robert Cornog has over 26 years of experience in product development and process design. Across a broad range of dosage forms and ...

About Robert
Brad Rowe

Senior Director, Integrated Development

Brad Rowe joined the organization in 2005 and is based from our Philadelphia, PA sites in Garnet Valley and Boothwyn. He joined QS...

About Brad
Meet More of Our Experts

More about our solubility enhancement capabilities

Browse More
Solubility Enhancement, Drug Product
How to Address Poor Solubility: A Data-Driven Path to Success (Infographic)
25 September 2026
Download Now
Solubility Enhancement, Drug Product
Poor Solubility as a Program-Level Risk: How to Make Better Formulation Decisions
25 September 2026
Download Now
Modified Release, Formulation Development, Translational Pharmaceutics
Alternative Strategies for Development of Modified Release Dosage Forms
Download Now
Translational Pharmaceutics, Formulation Development
On-Demand: Leveraging Real-Time Clinical Data to Deliver Certainty in Solubility Enhancement and Modified Release Development
12 December 2024
Watch recording
Browse More
Let's Talk
Humanity can't wait, so neither can we. Discuss your drug program today.
Contact Us Ask the Experts